<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3677">
  <stage>Registered</stage>
  <submitdate>5/10/2012</submitdate>
  <approvaldate>5/10/2012</approvaldate>
  <nctid>NCT01723982</nctid>
  <trial_identification>
    <studytitle>Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions</studytitle>
    <scientifictitle>A Randomised, Placebo-controlled, Double-blind, Parallel Groups, Multinational, Multicentre Trial Assessing the Effect of Barusiban Administered Subcutaneously on the Day of Transfer on Implantation and Pregnancy Rates in IVF/ICSI Patients</scientifictitle>
    <utrn />
    <trialacronym>BASIC</trialacronym>
    <secondaryid>2012-001622-10</secondaryid>
    <secondaryid>000048</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Barusiban (FE 200440)
Treatment: drugs - Placebo Comparator

Experimental: A. FE 200440 - Barusiban (FE 200440) Solution for Injection for Subcutaneous use

Placebo Comparator: B. Placebo - Placebo Solution for Injection for Subcutaneous use


Treatment: drugs: Barusiban (FE 200440)


Treatment: drugs: Placebo Comparator


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ongoing implantation rate</outcome>
      <timepoint>10-11 weeks after embryo transfer</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Ongoing pregnancy rate</outcome>
      <timepoint>10-11 weeks after transfer</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Implantation rate</outcome>
      <timepoint>5-6 weeks after transfer</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical pregnancy rate</outcome>
      <timepoint>5-6 weeks after transfer</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Positive Beta Human Chorionic Gonadotrophin (ßhCG) rate</outcome>
      <timepoint>13-15 days after transfer</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum barusiban concentration at the expected tmax</outcome>
      <timepoint>30 min after 2nd IMP administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency and intensity of adverse events</outcome>
      <timepoint>Within 60 days of oocyte retrieval +1 day until 10 -11 weeks after embryo transfer</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency and intensity of injection site reactions</outcome>
      <timepoint>Immediately and 30 min after each administration of IMP</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Women aged 18-37 years

          -  Women who have undergone 2-4 previous fresh in vitro fertilization (IVF) or
             intracytoplasmatic sperm injection (ICSI) cycles that all resulted in a negative ßhCG
             test, despite transfer of at least one embryo/blastocyst of good quality

          -  Women who have in the current controlled ovarian stimulation cycle for IVF/ICSI
             followed the long Gonadotrophin Releasing Hormone (GnRH) agonist or GnRH antagonist
             protocol, received hCG for triggering of final follicular maturation and have
             undergone oocyte retrieval for IVF/ICSI with the purpose of fresh transfer

          -  Retrieval of at least 6 oocytes in the current controlled ovarian stimulation cycle

          -  Subjects should have at least one embryo of good quality available for transfer on day
             3, or at least one good quality blastocyst available for transfer on day 5</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>37</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  A total of 6 or more controlled ovarian stimulation cycles for IVF/ICSI

          -  Abnormal karyotype

          -  Uterine pathology or hydrosalpinx

          -  Diagnosed with acquired or congenital thrombophilia disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>256</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Westmead Fertility Centre - Westmead</hospital>
    <hospital>Monash IVF - Clayton</hospital>
    <hospital>Melbourne IVF - Melbourne</hospital>
    <postcode> - Westmead</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ferring Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial investigates the effects of FE 200440 compared to placebo on implantation rate in
      women undergoing IVF/ICSI treatment</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01723982</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Development Support</name>
      <address>Ferring Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>